This webinar takes place on Wednesday March 26th between 16.00 and 16.45 CET / 15.00-15.45 GMT / 11.00-11.45 AM EDT / 8.00-8.45 AM PDT.

Follow the link to register for the webinar. Please note that the presentation will be given during the live event only and on demand viewing at a later date will not be possible. Contact us for any questions.

 

REGISTER FOR LIVE WEBINAR

 

THIS WEBINAR IS ARRANGED BY CELLECTRICON AB. FOR MORE INFORMATION ON THE HANDLING OF YOUR PERSONAL INFORMATION, SEE OUR PRIVACY POLICY

Abstract:

Dysfunction of microglia has been linked to a variety of CNS disorders including neurodegenerative and neuropsychiatric diseases and optic neuropathy. Cellectricon has developed an in vitro neuroinflammation platform that integrates human iPSC-derived microglia into rodent primary neuron-astrocyte co-cultures. The co-culture system recapitulates many aspects of chronic neuroinflammation and enables high-capacity studies that are relevant to neuroinflammation and microglial biology.

A number of functional and endpoint readouts have been developed, such as high content imaging quantification of the cellular phenotype of microglia and other cell types, multiplexed analysis of pro- and anti-inflammatory cytokines, and neuronal excitability analysis.

In this webinar, we will showcase how the platform captures mechanisms highly relevant for neuroinflammation, as supported by results from the evaluation of commercially available compounds. Furthermore, results support the use of multiple endpoints of microglial functional state to fully characterize and understand the pharmacology of compounds of interest.

 

Presented by:

CSO, Cellectricon AB

Johan Pihl

Johan joined Cellectricon in 2005 and has been in R&D as well as commercial positions at the company. He has been involved in the development of Cellectricon’s proprietary technology platforms and intellectual property. Prior to his role as Chief Scientific Officer at Cellectricon, he was developing and overseeing the discovery services as Chief Operating Officer. Johan has a PhD in Chemistry from Chalmers University of Technology, Gothenburg, Sweden, and is the author and co-author of numerous scientific publications and patents.
CSO, FireCyte Therapetics

Jonathan Levenson

Dr. Levenson is the Chief Scientific Officer at FireCyte Therapeutics and has over 16 years of experience as a neuroscientist in neuropsychiatry, neurodegeneration, and neuroinflammation. He has a Ph.D. in Biology from the University of Houston and did his postdoctoral training at the Baylor College of Medicine in the Department of Neuroscience. Prior to FireCyte, Dr. Levenson was Vice President of Translational Medicine at Tiaki Therapeutics, where he helped develop an integrated neuroinflammatory translational platform that more faithfully recapitulated disease processes occurring in patients. He was the head of preclinical and nonclinical research and development at Proclara Biosciences, where he was key in moving two assets that targeted and remodeled amyloid aggregates from early research into the clinic. He has held academic appointments at the University of Wisconsin-Madison and the Baylor College of Medicine.